Funding News Edition: July 21, 2021 See more articles in this edition
The AIDS Clinical Trials Group (ACTG) is an NIAID-supported network conducting research to improve the treatment of HIV and its co-infections and advance approaches to ultimately cure HIV. ACTG, in partnership with NIAID’s Division of AIDS, recently announced an opportunity for collaboration and funding of Small Clinical Trials Advancing HIV Remission and Cure. Consider applying if you’re able to propose experimental science clinical trials addressing questions important to ACTG’s HIV cure agenda, like quantifying and characterizing HIV reservoirs and their decay or immune-based therapies to clear virus expressing cells or control HIV reservoirs.
You can begin preparing an application on August 15, 2021, and the first due date is September 1, 2021 (with biannual due dates on March 1 and September 1 to follow).
Keep in mind, this is not an NIH funding opportunity announcement, so while you may consider general advice about applying for a grant from our website, ultimately you must follow ACTG’s policies and procedures. ACTG will evaluate proposals for merit, with the budget developed and finalized after the concepts are approved. Direct any inquiries to ACTGLeadershipSupport@DLHCorp.com.